YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient,
randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets
Primary Endpoint in Patients with Post-Surgical Pain
MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced top-line results from its
randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) in opioid naivepatients with post-operative pain following orthopedic surgery.AeroLEF(TM) met the pr...
Randomized Phase III Trial Showed Erbitux Significantly Improved
Secondary Endpoints of Progression-Free Survival and Disease
Control in Metastatic Colorectal Cancer Patients
- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a
randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...